 |
市場調查報告書
全球念珠菌藥物市場：未來前景（2020-2027）Global Candidiasis Therapeutics Market - 2020-2027 |
||||||
| 出版商 | DataM Intelligence | 商品編碼 | 961508 | ||||
| 出版日期 | 按訂單生產 | 內容資訊 | 英文 商品交期: 請詢問到貨日 |
||||
| 價格 |
|
||||||
| 全球念珠菌藥物市場：未來前景（2020-2027） Global Candidiasis Therapeutics Market - 2020-2027 | ||
| 出版日期: 按訂單生產 | 內容資訊: 英文 |
|
念珠菌藥物的全球市場受到以下因素的影響，例如研發活動（R＆D）的增加，感染病例的數量增加，免疫力減弱的患者人數的增加以及對各種治療方法的興趣增加。在該支持下，預計未來的擴展趨勢將繼續。另一方面，與替代療法的競爭會阻礙市場的增長。按類型劃分，對生殖器陰道念珠菌病（VVC）的需求有望在未來顯著增長。按地區劃分，北美國家是最大的市場。
本報告分析了念珠菌藥物的全球市場，並按類型，藥物類別和給藥方式分析了市場的基本結構和最新情況，整體市場趨勢的展望（未來8年）。我們正在按路線/分銷渠道和地區，主要市場促銷/限制因素，市場競爭結構，主要公司的概況，業務策略等調查詳細趨勢。
The global candidiasis therapeutics Market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).
Candidiasis, also known as thrush is a type of fungal infection which can affect men and women of all age groups. When the infection spreads into the throat, it causes esophagitis. It is also known by several different names such as moniliasis, candidosis, and oidiomycosis. The effects of this infection can be seen on internal, dermal, internal and systemic level wherein it is known as candidemia or intestinal thrush. The market is growing due to the widespread occurrence of this infection, limited efficacious antifungals as well as the lack of reliable treatments. Some of the major drug classes for the treatment of candidiasis include azoles, polyenes and echinocandins.
The global candidiasis therapeutics market growth is driven by the rising number of candidiasis infection cases globally, an increase in the susceptible immune-compromised patient pool, and growing awareness towards different treatments for candidiasis infection.
Increasing research and development for candidiasis treatment
The global candidiasis market is expected to grow significantly over the forecast period due to growing research & development for novel medications for the treatment of invasive fungal infections caused by Candida albicans. For instance, in October 2018, some of the researchers at the American Society for Microbiology found a compound alexidine dihydrochloride, which has the highest antifungal and anti-biofilm activity against a diverse range of fungal pathogens, hence having a greater potential for use as a pan-antifungal drug.
Rising number of patients with different candidiasis infection
The increasing number of patients affected by candidiasis infection is also one of the major factor driving the growth of the candidiasis treatment market. According to the Center for Disease Control and Prevention (CDC), about 46,000 cases of healthcare-associated invasive candidiasis occur annually, in the United States. The 30-day all-cause (crude) mortality among people with candidemia is around 30%. However, as people who infect from invasive candidiasis commonly have pre-medical disorders, it is ambiguous to determine the proportion of deaths directly attributable to the infection. Hence, this rise in the number of patients has helped in impelling the growth of the overall market.
Availibility of alterate treatments if likely to hinder the market growth
However, easy access to alternative treatment methods such as over-the-counter treatments and side-effects caused by these drugs are expected to hamper the market growth.
Epidemiology forecast
Oral candidiasis is one of the most common fungal infection of the mouth and represents the most common opportunistic for oral infection in humans. Infections of the mouth occur in about 6% of babies less than a month old. Around 20% of those receiving chemotherapy for cancer and 20% of those with AIDS also develop this infection.
An estimated 20% of women are likely to be asymptomatically colonized by vaginal yeast. In the United States, there are around 1.4 million doctor office visits every year for candidiasis. About three-quarters of the women have at least one yeast infection at some time during their lives.
Oesophagal candidiasis is the most common oesophagal infection in persons with AIDS and accounts for about 50% of all oesophagal infections, often coexisting with other oesophagal diseases. About two-thirds of people with AIDS and oesophagal candidiasis also have oral candidiasis.
Candida is the fourth most common cause of bloodstream infections among hospital patients in the U.S. During 2013-2017; the average incidence was approximately 9 per 100,000 people; however, this number varies substantially by geographic location and patient population. As per the Centers for Disease Control and Prevention (CDC), approximately 25,000 cases of candidemia occur nationwide each year.
The epidemiology forecast of candidiasis is covered for major countries including the U.S., Canada, Japan, U.K., Germany, France, Italy, and Spain. It covers estimated prevalent population and treated patient population for the forecast period 2020-2027 as well.
Pipeline Analysis
As of March 2019, the candidiasis therapeutics pipeline comprised more than 25 drugs in different stages of development.
A number of drug manufacturers are actively involved in the development of candidiasis therapeutics. For instance,
Hence, with positive clinical trial results and growing adoption of collaboration strategies are enhancing candidiasis therapeutics pipeline.
In addition, the issuance of patents helps in achieving different milestones in the form of grants and designations from regulatory bodies and institutes, including the National Institutes of Health (NIH), the U.S. Food and Drug Administration (USFDA), the European Medicines Agency (EMA), among others.
COVID-19 Impact Analysis
The market for candidiasis therapeutics is expected to grow significantly due to the rising cases of COVID-19 cases globally. There is an increased risk for critically ill COVID-19 patients to develop co-infection with Candida, which is likely to increase mortality rates. Despite the progress in public health and hospital care, infections continue to develop in hospitalised patients with COVID-19. COVID-19 patients in ICU, are at high risk of developing nosocomial infections associated with MV and respiratory manifestation. The main risk factors for invasive candidemia patients include prolonging hospital stays, CVC, surgical procedure and the use of broad-spectrum antibiotics. The high mortality increase the demand for early recognition of candidemia, and appropriate antifungal therapy are basic requirements to improve the outcome of COVID-19 patients in ICU. Hence, with rising demand for treatment of rising cases, there is a significant increase in research & development for the treatment of these infections, hence, expected to boost the market growth over the forecast period.
By product type, the candidiasis therapeutics market is classified into oral candidiasis, vulvovaginal candidiasis, cutaneous candidiasis, invasive candidiasis, and systemic candidiasis.
Vulvovaginal Candidiasis (VVC) segment is expected to grow at the fastest CAGR during the forecast period (2020-2027)
Vulvovaginal Candidiasis (VVC), also known as a vaginal yeast infection due to Candida, is the second most common cause of vaginitis. VVC infections are commonly caused by Candida albicans, fluconazole-resistant Candida strains, such as Candida glabrata. VVC is associated with substantial morbidity, including significant genital discomfort, psychological distress, reduced sexual pleasure, and loss of productivity. Some of the common VVC symptoms include vaginal soreness, pruritus, irritation, abnormal vaginal discharge, and excoriation of the vaginal mucosa. About 70-75% of women globally have at least one episode of vulvovaginal candidiasis in their lifetime, and around 40-50% of them experience two or more episodes. Approximately 6-8% of women with VVC suffer from recurrent disease, defined as experiencing at least three outbreaks within 12 months.
Some of the treatments available for vulvovaginal candidiasis include topical azole antifungals such as miconazole, clotrimazole, others and fluconazole, the only orally-administered antifungal currently approved for the treatment of VVC in the United States. Fluconazole reported a 55% therapeutic cure rate in its label, which now also includes warnings of the potential for fetal harm, illustrating the need for new oral alternatives. The conditions of women with moderate-to-severe VVC, VVC caused by fluconazole-resistant Candida spp, recurrent VVC, and VVC during child-bearing age are not fully treated by oral fluconazole or topical products. Also, there are no oral alternatives for VVC patients who do not respond to or do not tolerate fluconazole, and there are no FDA-approved products for the prevention of recurrent VVC.
On the basis of drug class, the candidiasis therapeutics market is classified into Polyene, Azole Antifungals, Topical azoles, Glucan synthesis inhibitors (echinocandins), Antimetabolite, Allylamines, and others.
Azoles Antifungals are expected to dominate the candidiasis therapeutics market during the forecast period
Azoles Antifungals are synthetic compounds which include two groups, imidazoles and triazoles. Imidazole agents include miconazole, ketoconazole, and clotrimazole. In August 2013, the FDA announced that clinicians should no longer prescribe ketoconazole (Nizoral, Janssen Pharmaceuticals) tablets as first-line therapy for any fungal infection, including Candida and dermatophyte infections, because of the adrenal insufficiency, risk for severe liver injury, and adverse drug interactions. Ketoconazole tablets were also withdrawn from the market in the European Union in July 2013.
Triazole agents are now the most commonly used azoles, include itraconazole, fluconazole,terconazole , butoconazole, econazole, and tioconazole. Recent triazoles ( such as, posaconazole, voriconazole, ravuconazole) are active against fluconazole-resistant strains of Candida. Posaconazole and Voriconazole and have shown high efficacy against candidiasis in recent clinical trials.
Geographical Analysis
North America region holds the largest market share global candidiasis therapeutics market
North America region is dominating the global candidiasis therapeutics market accounted for the largest market share in 2019, owing to the large investment in healthcare and growing awareness towards the candidiasis disorder. The candidiasis disease is increasing rapidly in the United States and is not restricted to any particular region. The market for systemic candidiasis is increasing in this region. Candida is one of the major cause of healthcare-associated bloodstream infections in U.S. hospitals. Thrush occurs in around 2-5% of healthy newborns and affects mainly during their first year of life. More than one million adult women and adolescent girls in the United States develop vaginal yeast infections annually. Hence, the high incidence rate of candidiasis is expected to drive the growth of the market in this region.
These infections are also costly for patients and healthcare facilities. Each case of candidemia is estimated to result in an additional 3 to 13 days of hospitalization and $6,000 to $29,000 in healthcare costs.15 Although antifungals can be used to treat most candidemia, some types of Candida are increasingly resistant to the antifungal drugs commonly used for treatment, such as the echinocandins (anidulafungin, caspofungin, and micafungin) and fluconazole.
The candidiasis therapeutics market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Cidara Therapeutics Inc., NovaDigm Therapeutics Inc., Amplyx Pharmaceuticals Inc., Astellas Pharma Inc., Basilea Pharmaceutica Ltd., Merck, SCYNEXIS, Inc., Pacgen Biopharmaceuticals, Viamet Pharmaceuticals Holdings, LLC, Mycovia Pharmaceuticals Inc., Novabiotics Limited, Bayer AG, among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the candidiasis therapeutics market globally.
Cidara Therapeutics Inc.
Overview: Cidara Therapeutics was founded in 2012 and headquartered in San Diego, California. It is a biotechnology company that specializes in the fields of healthcare and therapeutics. The company focuses on developing innovative therapies to treat life-threatening illnesses exacerbated by deficiencies of the human immune system. In 2019, Cidara was named a San Diego Metro Area top workplace for the third consecutive year by the San Diego Union-Tribune.
Product Portfolio: The Company's portfolio comprised its lead Phase 3 antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) targeting influenza and other viral diseases from Cidara's proprietary Cloudbreak® antiviral platform.
Key Development: In May 20, 2020, Cidara Therapeutics, Inc. announced that the first patient has been dosed in its ReSPECT pivotal Phase 3 clinical trial evaluating the efficacy and safety of the company's lead antifungal candidate, rezafungin. Rezafungin is a novel once-weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as candidemia and invasive candidiasis.
Mergers and Acquisitions: On July 2020, ANI Pharmaceuticals, Inc. published that they are expected a acquisition of Fluconazole Tablets USP, 50mg, 100mg, 150mg, and 200mg from a private company for $3.0 million. The current annual U.S. market for this product is approximately $40 million.
The global candidiasis therapeutics market report would provide an access to an approx. 69 market data table, 68 figures and 300 pages.
LIST NOT EXHAUSTIVE
